Format

Send to

Choose Destination
World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Author information

1
a Department of Psychiatry and Psychotherapy , Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg , Erlangen , Germany.
2
b Department of Neurodegeneration Diagnostics , Medical University of Białystok , and Department of Biochemical Diagnostics , University Hospital of Białystok , Białystok , Poland.
3
c Center of Mental Health, Clinic and Policlinic of Psychiatry, Psychosomatics and Psychotherapy , University Hospital Würzburg , Würzburg , Germany.
4
d Institute for Healthy Aging , University of North Texas Health Science Center , Fort Worth , TX , USA.
5
e Department of Neurology , Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center , Nijmegen , The Netherlands.
6
f Department of Laboratory Medicine , Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer center , Nijmegen , The Netherlands.
7
g Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Salpêtrièrie Hospital, INSERM UMR-S 975 (ICM), Paris 6 University , Paris , France.
8
h Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience , Alzheimer Center Limburg, Maastricht University , Maastricht , The Netherlands.
9
i Department of Neurology , Alzheimer Centre, Amsterdam Neuroscience VU University Medical Centre , Amsterdam , The Netherlands.
10
j Institute of Clinical Neurobiology , Vienna , Austria.
11
k Reference Center for Biological Markers of Dementia (BIODEM) , University of Antwerp , Antwerp , Belgium.
12
l Department of Neurology and Memory Clinic , Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken , Antwerp , Belgium.
13
m Department of Psychiatry and Psychotherapy , University of Bonn , Bonn , Germany.
14
n Institute of Human Genetics , University of Bonn , Bonn , Germany.
15
o Department of Psychiatry and Psychotherapy , University of Cologne , Cologne , Germany.
16
p Section of Neurology, Center for Memory Disturbances, Lab of Clinical Neurochemistry , University of Perugia , Perugia , Italy.
17
q Department of Radiology , Mayo Clinic , Rochester , MN , USA.
18
r Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience , VU University Medical Center Amsterdam , Amsterdam , The Netherlands.
19
s AXA Research Fund & UPMC Chair , Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital , Paris , France.
20
t Department of Neurology , Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona , Barcelona , Spain.
21
u Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas , CIBERNED , Spain.
22
v German Center for Neurodegenerative Disorders (DZNE) , Bonn , Germany.
23
w Center for Brain Health, Department of Psychiatry , NYU Langone Medical Center , New York , NY , USA.
24
x Knight Alzheimer's Disease Research Center , Washington University School of Medicine , Saint Louis , MO , USA.
25
y Department of Neurology , Washington University School of Medicine , Saint Louis , MO , USA.
26
z Barcelonabeta Brain Research Center , Pasqual Maragall Foundation , Barcelona , Spain.
27
aa Alzheimer's Disease and Other Cognitive Disorders Unit , Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain.
28
ab Karolinska Institutet , Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics , Huddinge , Sweden.
29
ac Department of Pathology and Laboratory Medicine, Perelman School of Medicine , University of Pennsylvania , Philadelphia , PA , USA.
30
ad Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , Mölndal , Sweden.
31
ae Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.
32
af Department of Neurology , University of Ulm , Ulm , Germany.
33
ag Paracelsus-Elena-Klinik, Kassel and University Medical Center Göttingen, Department of Neurology , Göttingen , Germany.
34
ah Department of Psychiatry & Psychotherapy , University of Göttingen , Göttingen , Germany.
35
ai German Center for Neurodegenerative Diseases (DZNE) , Göttingen , Germany.
36
aj iBiMED, Medical Sciences Department , University of Aveiro , Aveiro , Portugal.
37
ak Nuffield Department of Clinical Neurosciences , University of Oxford , Oxford , UK.
38
al Clinical Dementia Centre, Department of Neurology , University Medical School , Göttingen , Germany.
39
am Laboratory of Neurosciences , National Institute on Aging/National Institutes of Health (NIA/NIH) , Baltimore , MD , USA.
40
an Department of Radiology , Washington University School of Medicine , Saint Louis , MO , USA.
41
ao Department of Neurosurgery, HSC T-12/086 , Stony Brook University , New York , NY , USA.
42
ap Departamento de Ciencias Celulares y Moleculares/Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía , Universidad Peruana Cayetano Heredia , Lima , Peru.
43
aq Chair of Psychoneuroimmunoendocrinology , Maimonides University , Buenos Aires , Argentina.
44
ar Department of Psychiatry , University Hospital Cochin-Site Tarnier 89 rue d'Assas, INSERM 894, Faculty of Medicine Paris Descartes , Paris , France.
45
as Department of Molecular Neuroscience , UCL Institute of Neurology , London , UK.

Abstract

In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

KEYWORDS:

Alzheimer’s disease; biomarkers; cerebrospinal fluid; consensus; dementia

PMID:
29076399
PMCID:
PMC5916324
[Available on 2019-06-01]
DOI:
10.1080/15622975.2017.1375556
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center